Novartis Entresto® US patent upheld by US Court of Appeals
Portfolio Pulse from
The US Court of Appeals for the Federal Circuit has upheld the validity of Novartis' patent for Entresto®, a combination drug of sacubitril and valsartan. This decision is favorable for Novartis, ensuring continued market exclusivity for Entresto® in the US.
January 13, 2025 | 6:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The US Court of Appeals has upheld Novartis' patent for Entresto®, ensuring continued market exclusivity in the US. This is a positive development for Novartis, likely supporting its revenue from this key product.
The court's decision to uphold the Entresto® patent is crucial for Novartis as it maintains market exclusivity, preventing generic competition. This is likely to positively impact Novartis' revenue from Entresto®, a significant product in its portfolio.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90